KUALA LUMPUR: The Ministry of Health (MOH) and the Institute for Clinical Research (ICR) have started clinical trials to study the use and efficacy of Ivermectin for high-risk COVID-19 patients at 12 MOH's hospitals.
Health director-general Tan Sri Dr Noor Hisham Abdullah said Ivermectin is a Food and Drug Administration (FDA) approved antiparasitic drug widely used for treating several neglected tropical diseases, including onchocerciasis, strongyloidiasis and helminthiases, however, the evidence is inconclusive to recommend routine use of Ivermectin for COVID-19 patients.
"The 'off-label' use of Ivermectin gained global attention due to some promising results by case studies and clinical trials.
"The FDA has not approved Ivermectin for use in treating or preventing COVID-19 in humans, and the World Health Organisation (WHO) only recommends the use of Ivermectin in a clinical trial setting, in which patients are monitored closely by experienced clinicians and researchers for safety and efficacy," he said in a statement today.
He said there is an ongoing need for adequately powered, well-designed, and well-conducted clinical trials for evidence-based guidance on the role of Ivermectin in the treatment of COVID-19.
NOOR HISHAM-IVERMECTIN 2 KUALA LUMPUR
"Under the circumstances, MOH and ICR have initiated a multicentre open-label randomised controlled trial...the Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients (I-TECH Study) headed by Infectious Disease physician at Raja Permaisuri Bainun Hospital, Ipoh and a team of specialists and Clinical Research Centres (CRC) at 12 MOH hospitals," he said.
Dr Noor Hisham said the trial was approved by the ministry's Medical Research and Ethics Committee on May 25, where the study compares Ivermectin treatment (specific dose with specific duration) with the standard of care alone.
He said the study would enrol 500 subjects from high-risk groups aged 50 years and above admitted to MOH hospitals with mild or moderate COVID-19 symptoms (stage two to three).
"The study aims to determine the efficacy of Ivermectin in preventing the progression of COVID-19 to severe disease (stage four and five) and in terms of mortality outcomes.
"ICR has set up a Data Monitoring Board (DMB) consisting of independent ID physicians, clinical trial pharmacists and methodological experts to safeguard the trial patients on the safety and efficacy of the investigation product set by the National Pharmaceutical Regulatory Agency (NPRA)," he said.
NOOR HISHAM-IVERMECTIN 3 (LAST) KUALA LUMPUR
He added the First-Patient-In (FPI) was on May 31 this year and to date, eight patients have been enrolled, where the study is expected to be completed by Sept 2021.
Meanwhile, Dr Noor Hisham said the WHO COVID-19 Solidarity Trial for COVID-19 Treatments (SOLIDARITY) which included Malaysia, found insufficient evidence for the use of Remdesivir, Hydroxychloroquine, Interferon and Lopinavir in terms of mortality outcomes.
He said currently the Malaysian Consensus Management Guidelines for COVID-19 maintains Favipiravir as the only antiviral therapy for the management of COVID-19 cases, adding even this recommendation may change as more evidence becomes available.
"The COVID-19 clinical characterisation study by MOH specialists and researchers found that for cases admitted to hospitals, 95 per cent had a mild illness but about 3.5 per cent subsequently progressed to severe disease.
"They were mostly of the older age of more than 51-year-old or had underlying co-morbidities such as chronic kidney disease and chronic pulmonary disease that increased their risk for severe disease... however, for high-risk COVID-19 patients, many repurposed antiviral therapies were found ineffective," he said.
Meanwhile, he said the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial showed dexamethasone, a steroid, improved mortality outcomes for COVID-19 patients in the severe stage of disease when oxygen supplementation or mechanical ventilation is required.
"But for the management of mild and moderate cases, there is lack of treatment, either to prevent disease progression or cut viral transmission," he said, adding effective pharmacologic treatments for COVID-19 remains a challenge.
-- BERNAMA
Bernama
Sat Jun 05 2021
Dr Noor Hisham said the Ministry of Health (MOH) and the Institute for Clinical Research (ICR) have started clinical trials to study the use and efficacy of Ivermectin for high-risk COVID-19 patients at 12 MOH's hospitals. - BERNAMA filepic
Putin says Russia willing to seek compromises between Iran and Israel
Russia is ready to help seek compromises between arch-foes Israel and Iran, President Vladimir Putin said on Friday, saying these would be difficult but possible.
What proposals will Russia push at the BRICS summit?
The proposal is also to establish a BRICS reinsurance company to allow uninterrupted shipment of goods and key commodities between members.
Indonesia's free meals plan in the spotlight as Prabowo readies for office
Prabowo calls the programme one of the main drivers of economic growth, eventually set to add an estimated 2.5 million jobs.
Astro AWANI's revamped English news website, AWANI International, launches on Oct 21
Astro AWANI's revamped English platform delivers in-depth global news and expert analysis to keep you informed on key developments.
Israeli strikes kill 33 people in Jabalia refugee camp in Gaza, medics say
Residents of Jabalia said Israeli tanks had reached the heart of the camp after pushing through suburbs and residential districts.
Liam Payne's ex-partner calls for media restraint after 'painful' death
Cheryl Tweedy used her statement to urge the media to remember they had a seven-year-old son, Bear, who could read the reports.
Analysts: Indonesia's strong MoF leadership team to boost investor confidence
Sri Mulyani Indrawati as head of Indonesia's Ministry of Finance is expected to instil confidence among investors.
Biden offers both a carrot and a stick to Israel as his term nears an end
Israel has frequently resisted US advice and has caused political difficulties for the Biden administration.
Putin says BRICS will generate most of global economic growth
Russian President Vladimir Putin will host a summit of the group in the city of Kazan on Oct. 22-24.
ISIS Malaysia's perspective of Budget 2025
An excellent rakyat-centric budget under the overarching principle of a caring and humane economy.
Budget 2025: Record increase in STR, SARA aid initiatives
The government will provide a significant boost to the Sumbangan Tunai Rahmah (STR) and Sumbangan Asas Rahmah (SARA) initiatives next year.
Budget 2025: EPF contributions to be made mandatory for foreign workers – PM Anwar
The government plans to make it compulsory for all non-citizen workers to contribute to the Employees Provident Fund (EPF).
What policies to expect from Indonesia's new President Prabowo
Prabowo will be open to foreign investment, his aide has said, such as by offering investors management of airports and sea ports.
Budget 2025: Govt allocates RM470 mil to empower women's participation in PMKS
The Women's Leadership Apprenticeship Program will be intensified as an effort to produce more female corporate personalities.
Israel sends more troops into north Gaza, deepens raid
Residents of Jabalia in northern Gaza said Israeli tanks had reached the heart of the camp, using heavy air and ground fire.
Indonesia ramps up security ahead of Prabowo's inauguration
Prabowo Subianto will be sworn in as Indonesia's president on Sunday with Vice President-elect, Gibran Rakabuming Raka, also taking office.
Immediate allocation of RM150 mil for local authorities, DID to tackle flash floods
Datuk Seri Anwar Ibrahim said this allocation is intended to address the recent flash floods that hit the capital and several major towns.
Budget 2025: Sabah, Sarawak to continue receiving among highest allocations - PM
Sabah and Sarawak continues to be prioritised under Budget 2025, with allocations of RM6.7 billion and RM5.9 billion respectively.
NFOF will be operational in November 2024 with funding of RM1 bil
PM Anwar Ibrahim said NFOF will support venture capital fund managers to invest in startup companies with RM300 million set aside for 2025.
Minimum wage to increase to RM1,700 effective Feb 1, 2025
The Progressive Wage Policy would be fully enforced next year with an allocation of RM200 million, benefiting 50,000 workers.